Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1419 in Advanced/Metastatic Solid Tumors
NCT06554795Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Sep 2024
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of DB-1419 in solid tumor, sponsored by Duality Biotherapeutics. Started Sep 2024; status: recruiting.
02
Drugs
DB-1419
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06554795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554795.